| Description | Felzartamab(MOR-202) is a human-targeted monoclonal antibody to CD38 for the study of multiple myeloma and advanced antibody-mediated rejection of allogeneic kidney transplants. |
| In vitro | MOR202-mediated toxic effects on multiple myeloma (MM) cell lines can be enhanced by the proteasome inhibitor bortezomib (BOR) and the immunomodulator lenalidomide (LEN).[1] |
| In vivo | MOR202 (12 mg/kg; murine MM models) dose-dependently reduced osteolysis by up to 55%. Coadministration with 0.6 mg/kg BOR or 50 mg/kg LEN completely eliminated osteolysis at a low dose of 3 mg/kg.[1] |
| Synonyms | TJ-202, MOR-03087, MOR-202 |
| molecular weight | N/A |
| CAS | 2197112-39-1 |
| Storage | store at low temperature | store at -20°C |
| References | 1. Endell J, et al. Effect of MOR202, a human CD38 antibody, in combination with lenalidomide and bortezomib, on bone lysis and tumor load in a physiologic model of myeloma. Journal of Clinical Oncology, 2011, 29(15_suppl): 8078-8078. 2. Gschwend N, et al. Spätergebnisse der Colonna-Arthroplastik [Late results of the Colonna arthroplasty]. Orthopade. 1988 Nov;17(6):472-8. |